Lassa Fever - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Lassa Fever - Pipeline Review, H1 2016

Lassa Fever - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Lassa Fever - Pipeline Review, H1 2016
Published Jun 15, 2016
54 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Lassa Fever - Pipeline Review, H1 2016, provides an overview of the Lassa Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lassa Fever
- The report reviews pipeline therapeutics for Lassa Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lassa Fever therapeutics and enlists all their major and minor projects
- The report assesses Lassa Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lassa Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lassa Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lassa Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8197IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Lassa Fever Overview71
Therapeutics Development82
  Pipeline Products for Lassa Fever Overview81
  Pipeline Products for Lassa Fever Comparative Analysis91
Lassa Fever Therapeutics under Development by Companies101
Lassa Fever Therapeutics under Investigation by Universities/Institutes111
Lassa Fever Pipeline Products Glance121
  Early Stage Products121
Lassa Fever Products under Development by Companies131
Lassa Fever Products under Investigation by Universities/Institutes141
Lassa Fever Companies Involved in Therapeutics Development156
  Arno Therapeutics, Inc.151
  Celgene Corporation161
  Etubics Corporation171
  Kineta, Inc.181
  Profectus BioSciences, Inc.191
  SIGA Technologies, Inc.201
Lassa Fever Therapeutics Assessment219
  Assessment by Monotherapy Products211
  Assessment by Target222
  Assessment by Mechanism of Action242
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Drug Profiles3020
  AR-12 Drug Profile303
  CC-11050 Drug Profile331
  DEF-201 Drug Profile342
  FBH-003 Drug Profile361
  FDX-000 Drug Profile371
  KIN-1400 Drug Profile381
  lassa fever vaccine Drug Profile391
  lassa fever vaccine Drug Profile401
  lassa fever vaccine 1 Drug Profile411
  lassa fever vaccine 2 Drug Profile421
  LHF-535 Drug Profile431
  Monoclonal Antibodies for Lassa Fever Drug Profile441
  Monoclonal Antibodies for Viral Infections Drug Profile452
  Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus Drug Profile471
  ST-193 Drug Profile482
Lassa Fever Dormant Projects501
Lassa Fever Product Development Milestones512
  Featured News &Press Releases511
    May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials511
    Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals511
    May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research521
Appendix532
  Methodology531
  Coverage531
  Secondary Research531
  Primary Research531
  Expert Panel Validation531
  Contact Us531
  Disclaimer541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Lassa Fever - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Lassa-Fever-Pipeline-Review-H1-2016-2088-15951>
  
APA:
Global Markets Direct - Market Research. (2016). Lassa Fever - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Lassa-Fever-Pipeline-Review-H1-2016-2088-15951>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.